PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

N Yuki Selected Research

Syndrome

01/2005	Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain-Barré syndrome.
05/2003	Anti-GM1 antibody IgG subclass: a clinical recovery predictor in Guillain-Barré syndrome.
06/2002	Anti-GT1a IgG in Guillain-Barré syndrome.
12/2001	Differential immune response to gangliosides in Guillain-Barré syndrome patients from Japan and The Netherlands.
11/2001	[Anti-GQ1b IgG-negative case of overlapping Fisher's and Gullain-Barré syndromes after Campylobacter jejuni (PEN 19) enteritis]
08/2001	[Ataxic form of Guillain-Barré syndrome associated with anti-GD1b IgG antibody]
07/2001	Range of cross reactivity of anti-GM1 IgG antibody in Guillain-Barré syndrome.
07/2001	Overlapping Guillain-Barré syndrome and Bickerstaff's brainstem encephalitis associated with anti-GQ1b IgG antibody after herpes simplex virus infection.
02/2001	[Anti-GD1b IgG antibody-related Guillain-Barré syndrome initially mimicking brainstem infarction]
02/2001	Rapid resolution of nerve conduction blocks after plasmapheresis in Guillain-Barré syndrome associated with anti-GM1b IgG antibody.
01/2001	Anti-GQ1b IgG antibody syndrome: clinical and immunological range.
01/2001	Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.
10/2000	Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.
07/2000	Ataxic form of Guillain-Barr syndrome associated with anti-GD1b IgG antibody.
04/2000	Antibodies to GM1(NeuGc) in Guillain-Barré syndrome after ganglioside therapy.
03/2000	Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
02/2000	Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barré syndrome with antiganglioside antibodies.

Articles by Research Topic

Disease

17	Syndrome 01/2005 - 02/2000
3	Ataxia (Dyssynergia) 11/2004 - 08/2000
2	Infection 07/2001 - 10/2000
2	Chronic Hepatitis C 07/2001 - 12/2000
2	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 05/2001 - 06/2000
2	Ophthalmoplegia (External Ophthalmoplegia) 01/2001 - 08/2000
1	Speech Disorders (Cluttering) 02/2006
1	Diarrhea 02/2006
1	Polyneuropathies (Polyneuropathy) 08/2005
1	Miller Fisher Syndrome (Fisher Syndrome) 03/2004
1	Paralysis (Palsy) 07/2003
1	Intracranial Aneurysm (Cerebral Aneurysm) 01/2003
1	Oculomotor Nerve Diseases (Oculomotor Nerve Palsy) 09/2002
1	Enteritis 11/2001
1	Encephalitis (Encephalitis, Rasmussen) 07/2001
1	Brain Stem Infarctions (Weber Syndrome) 02/2001
1	Neuritis (Polyneuritis) 01/2001
1	Hepatitis C 03/2000

Drug/Important Bio-Agent (IBA)

18	Immunoglobulin G (IgG)IBA 11/2004 - 07/2000
5	AntibodiesIBA 02/2006 - 02/2000
2	InterferonsIBA 07/2001 - 12/2000
2	sulfate-3-glucuronyl paraglobosideIBA 05/2001 - 06/2000
2	Immunoglobulin M (IgM)IBA 05/2001 - 06/2000
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 08/2005
1	Immunoglobulins (Immunoglobulin)IBA 01/2005
1	Methylprednisolone FDA LinkGeneric 01/2005
1	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2003
1	GangliosidesIBA 12/2001
1	ganglioside M1b (GM1b)IBA 03/2000

Therapy/Procedure

1	Plasmapheresis 02/2001
1	Retreatment 12/2000
1	Renal Dialysis (Hemodialysis) 03/2000